<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS NINE MONTH SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
ABBOTT LABORATORIES' 1994 THIRD QUARTER FORM 10-Q AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FORM 10-Q FILING.
</LEGEND>
<MULTIPLIER> 1,000
       
                             
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1994
<PERIOD-START>                             JAN-01-1994
<PERIOD-END>                               SEP-30-1994
<CASH>                                         222,031
<SECURITIES>                                    96,656
<RECEIVABLES>                                1,590,088
<ALLOWANCES>                                   118,064
<INVENTORY>                                  1,057,111
<CURRENT-ASSETS>                             3,860,280
<PP&E>                                       6,904,109
<DEPRECIATION>                               3,081,122
<TOTAL-ASSETS>                               8,356,158
<CURRENT-LIABILITIES>                        3,407,765
<BONDS>                                        307,920
<COMMON>                                       500,539
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                   3,457,950
<TOTAL-LIABILITY-AND-EQUITY>                 8,356,158
<SALES>                                      6,674,095
<TOTAL-REVENUES>                             6,674,095
<CGS>                                        2,926,919
<TOTAL-COSTS>                                2,926,919
<OTHER-EXPENSES>                               711,176<F1>
<LOSS-PROVISION>                                 6,659
<INTEREST-EXPENSE>                              36,525
<INCOME-PRETAX>                              1,563,045
<INCOME-TAX>                                   468,914
<INCOME-CONTINUING>                          1,094,131
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,094,131
<EPS-PRIMARY>                                     1.34
<EPS-DILUTED>                                     1.33
<FN>
<F1>OTHER EXPENSES ARE RESEARCH AND DEVELOPMENT EXPENSES
</FN>